Striatal NELF-mediated RNA polymerase II stalling controls l -dopa induced dyskinesia
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Long-term l-3,4-dihydroxyphenylalanine (L-Dopa) treatment in Parkinson's disease leads to involuntary movements called dyskinesia, notably through an overexpression of immediate-early genes (IEG). Their rapid transcription involves the stalling of RNA polymerase II on IEG promoters, a mechanism that critically depends on the presence of the negative elongation factor (NELF) protein complex. We here down-regulated the key NELF-E subunit using lentiviral vector delivery of a short hairpin RNA in the striatum of 6-hydroxydopamine lesioned rats. Such NELF-E reduced expression significantly attenuated the development of abnormal involuntary movements in response to chronic L-Dopa treatment. Effectiveness of silencing was demonstrated by the significant decrease in striatal ∆FosB, ARC and Zif268 IEG expression. Repression of NELF-mediating RNA polymerase II stalling thus achieves both antidyskinetic and potentiation of antiparkinsonian L-Dopa effect, highlighting the role of transcriptional events in dyskinesia establishment, acute dyskinetic manifestation and in the therapeutic response to L-Dopa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
Yamaguchi, Y., Takagi, T., Wada, T., Yano, K., Furuya, A., Sugimoto, S., Hasegawa, J., & Handa, H. (1999) · Cell · doi:10.1016/s0092-8674(00)80713-8 · Cited by 841
Pathogenic Lysosomal Depletion in Parkinson's Disease
Dehay, B., Bové, J., Rodríguez-Muela, N., Perier, C., Recasens, A., Boya, P., & Vila, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1920-10.2010 · Cited by 825
Gerfen, C., Keefe, K., & Gauda, E. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-12-08167.1995 · Cited by 283 · cited 1×
“…markers, in particular the members of the immediate-early gene (IEG) family (Bastide et al., 2015), a class of genes rapidly transcribed in response to an external stimulus, including ΔFosB, ARC and Zif268 (Bastide et al., 2014; Berke et al., 1998; Gerfen et al., 1990, 1995; McClung et al., 2004).”
BackgroundHow do you treat motor complications in Parkinson's disease: medicine, surgery, or both?
Fahn, S. (2009) · Annals of Neurology · doi:10.1002/ana.21453 · Cited by 66
Cited by
Inflammatory process in Alzheimer's Disease
Meraz-Ríos, M. A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hernández, J., & Campos-Peña, V. (2013) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2013.00059 · Cited by 427
Interaction of aldehydes derived from lipid peroxidation and membrane proteins
Pizzimenti, S., Ciamporcero, E., Daga, M., Pettazzoni, P., Arcaro, A., Cetrangolo, G., Minelli, R., Dianzani, C., Lepore, A., Gentile, F., et al. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00242 · Cited by 380
Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences
Romoli, M., Mazzocchetti, P., D'Alonzo, R., Siliquini, S., Rinaldi, V. E., Verrotti, A., Calabresi, P., & Costa, C. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666181227165722 · Cited by 372
Cell Death Mechanisms in Stroke and Novel Molecular and Cellular Treatment Options
Sekerdag, E., Solaroglu, I., & Gursoy-Ozdemir, Y. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180302115544 · Cited by 369
Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update
Voon, V., Napier, T. C., Frank, M. J., Sgambato-Faure, V., Grace, A. A., Rodriguez-Oroz, M., Obeso, J., Bezard, E., & Fernagut, P.-O. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30004-2 · Cited by 359
Metadata
- Authors
- Bastide, M. F., Bido, S., Duteil, N., & Bézard, E.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2016-01
- Volume
- 85
- Pages
- 93-98
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2206023631
- Cited by
- 73
- References
- 5
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.